PHENYTOIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Phenytoin, and what generic alternatives are available?
Phenytoin is a drug marketed by Actavis Mid Atlantic, Pai Holdings Pharm, Taro, Vistapharm, Epic Pharma Llc, Rising, Aurobindo Pharma, Pharmeral, Watson Labs, Acella, Am Regent, Fresenius Kabi Usa, Hospira, Marsam Pharms Llc, Smith And Nephew, Solopak, Warner Chilcott, and West-ward Pharms Int. and is included in twenty-three NDAs.
The generic ingredient in PHENYTOIN is phenytoin sodium. There are twenty-one drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the phenytoin sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Phenytoin
A generic version of PHENYTOIN was approved as phenytoin sodium by WEST-WARD PHARMS INT on December 31st, 1969.
Summary for PHENYTOIN
US Patents: | 0 |
Applicants: | 18 |
NDAs: | 23 |
Finished Product Suppliers / Packagers: | 7 |
Raw Ingredient (Bulk) Api Vendors: | 155 |
Clinical Trials: | 127 |
Patent Applications: | 4,038 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for PHENYTOIN |
Drug Sales Revenues: | Drug sales revenues for PHENYTOIN |
What excipients (inactive ingredients) are in PHENYTOIN? | PHENYTOIN excipients list |
DailyMed Link: | PHENYTOIN at DailyMed |
Recent Clinical Trials for PHENYTOIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Sohag University | Phase 2/Phase 3 |
Dr Cipto Mangunkusumo General Hospital | Phase 4 |
Wayne State University | Phase 4 |